Results 101 to 110 of about 26,857 (227)

Activity of recombinant HIV-1 integrase on mini-HIV DNA

, 1999
Integration of the human immunodeficiency virus type 1 (HIV-1) cDNA into the genome of a human cell is an essential step in the viral replication cycle.
Cherepanov, Peter, De Clercq, Erik, Surratt, David, Debyser, Zeger, Pluymers, Wim, Toelen, Jaan, Griffith, Jack   +6 more
core   +1 more source

Characterization of HIV-1 Integrase Gene and Resistance Associated Mutations Prior to Roll out of Integrase Inhibitors by Kenyan National HIV-Treatment Program in Kenya

, 2020
BACKGROUND: Antiretroviral therapy containing an integrase strand transfer inhibitor plus two Nucleoside Reverse Transcriptase inhibitors has now been recommended for treatment of HIV-1-infected patients.
Lihana Raphael, Sepha, Mabeya, Nyerere Andrew, Nyamache Anthony, Ngugi Caroline   +4 more
core   +1 more source

The evolving role of structural biology in pharma: integration of X‐ray crystallography, cryo‐electron microscopy and beyond

Acta Crystallographica Section D, Volume 82, Issue 6, Page 587-602, June 2026.
This review describes how an integrated structural biology platform at Merck Sharp & Dohme LLC, Rahway, New Jersey, USA, combining X‐ray crystallography, cryo‐EM, MicroED and cryo‐ET, enables seamless three‐dimensional insights from molecular to cellular length scales.
Jill E. Chrencik, Hua-Poo Su, Yacob Gomez Llorente, Rachel L. Palte, Daniel J. Klein, Robert P. Hayes, Sadie P. Antine, Guilermo A. Asmar-Rovira, Nicole Bertoletti, Noel J. Byrne, Brittany L. Carroll, Ciro D. Cordeiro, Kaylynn Curfman, James Dutko, Michael J. Eddins, Thierry Fischmann, Barani Govindarajan, Corey W. Hecksel, Thu Ho, Kaspar Hollenstein, Mee Ra Hong, Alan Hruza, Andrii Ishchenko, Maru Jaime-Garza, Matt J. Jaremko, Hayley L. Knox, James Kostas, Harini Krishnamurthy, Ioannis Manolaridis, Cameron L. Noland, Andrea T. Partridge, Sangita B. Patel, Paul Reichert, John C. Reid, Catarina Felisberto-Rodrigues, Chitra A. Shintre, Jennifer M. Shipman, Elakkiya Tamilselvan, Morgan E. Walker, Susanne N. Walker, Renjing Wang, Katharine M. Wright, Tien-Jui Yen, Byung-Kuk Yoo, Sandra B. Gabelli   +44 more
wiley   +1 more source

Treatment durability, satisfaction and quality of life in virologically suppressed HIV‐1 people switching to doravirine: Results from the French study DoraVIH

HIV Medicine, Volume 27, Issue 6, Page 886-895, June 2026.
Abstract Objectives In Europe, most people with HIV‐1(PWH) achieve virologic suppression with effective and well‐tolerated antiretroviral therapies (ART). In this context, patient‐reported outcomes (PRO) are increasingly important for evaluating ART benefits.
Spire Bruno, Robineau Olivier, Pourcher Valérie, Loubet Paul, Palacios Christia, Jacomet Christine, Benachir Haydar, Mariot Philippe, Parienti Jean‐Jacques, Slama Laurence   +9 more
wiley   +1 more source

The impact of accumulating immune adaptation in circulating strains of HIV‐1

HIV Medicine, Volume 27, Issue 6, Page 918-934, June 2026.
Abstract Background Mutations in human immunodeficiency virus type 1 (HIV‐1) enable the virus to evade recognition and killing by human leucocyte antigen (HLA)‐restricted T cells. These viral adaptations are specific to the HLA type of individuals and are therefore evident as HLA allele‐HIV sequence associations at the population level. Most studies of
Marwah Al‐kaabi, Alison Castley, Pooja Deshpande, Abha Chopra, David Nolan, Simon Mallal, Mina John, Silvana Gaudieri   +7 more
wiley   +1 more source

Possible pharmacological target for inhibition of HIV integration

, 2023
The treatment of HIV/AIDS involves the use of multiple antiretroviral drugs categorized into six major classes that target different stages of the HIV life cycle.
Tokimitsu, Shigeki
core  

Real‐world use of second‐generation integrase strand transfer inhibitors (INSTI) as switch therapy in the prospective ANRS‐CO3‐AquiVIH‐NA cohort

HIV Medicine, Volume 27, Issue 6, Page 965-978, June 2026.
Abstract Objectives To characterize real‐world treatment switching in France to bictegravir (BIC or B) or dolutegravir (DTG)‐based regimens with a focus on treatment persistence, effectiveness (HIV‐1 RNA ≤50 copies/ml) and particular attention to the prevalence and incidence of comorbidities. Methods People living with HIV from the prospective ANRS‐CO3‐
O. Leleux, A. Peyrouny‐Mazeau, A. Perrier, M. Hessamfar, G. Le Moal, D. Neau, L. Alleman, C. Cazanave, E. Lazaro, P. Duffau, A. Riché, Y. Gérard, G. Barrière, S. Reigadas, M.‐A. Vandenhende, F. Bonnet   +15 more
wiley   +1 more source

HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland

BMC Infectious Diseases, 2012
Background HIV integrase inhibitor use is limited by low genetic barrier to resistance and possible cross-resistance among representatives of this class of antiretrovirals.
Parczewski Miłosz, Bander Dorota, Urbańska Anna, Boroń-Kaczmarska Anna   +3 more
doaj   +1 more source

Prevalence of Sleep Apnea and Sleepiness in Adults With and Without HIV in Mwanza, Tanzania: Baseline Results From an Ongoing Cohort Study

Journal of Sleep Research, Volume 35, Issue 3, June 2026.
ABSTRACT We conducted a cross‐sectional analysis of the baseline survey of participants aged > 30 years enrolled in the Mwanza HIV&CVD Cohort in Tanzania. Our primary objective was to examine the association between HIV status and sleep apnea (SA).
Godfrey A. Kisigo, Benson Issarow, Salama Fadhil, Grace Ruselu, Ponsiano Fabian, Ayubu Garbindi, Robert N. Peck, Kathy Baisley, Saidi Kapiga, Ana C. Krieger   +9 more
wiley   +1 more source

A hybrid lentivirus-transposon vector for safer gene therapy

, 2010
Gene therapy vectors based on the HIV-1 lentivirus are an attractive option for clinical applications because they enter a broad range of target cells efficiently and deliver stable gene expression through integration into host chromosomes.
Vink, C.A.
core